派博傳思國際中心

標(biāo)題: Titlebook: Cancer Gene Therapy; Past Achievements an Nagy A. Habib Book 2002 The Editor(s) (if applicable) and The Author(s), under exclusive license [打印本頁]

作者: Denial 時(shí)間: 2025-3-21 18:19
書目名稱Cancer Gene Therapy影響因子(影響力)

書目名稱Cancer Gene Therapy影響因子(影響力)學(xué)科排名

書目名稱Cancer Gene Therapy網(wǎng)絡(luò)公開度

書目名稱Cancer Gene Therapy網(wǎng)絡(luò)公開度學(xué)科排名

書目名稱Cancer Gene Therapy被引頻次

書目名稱Cancer Gene Therapy被引頻次學(xué)科排名

書目名稱Cancer Gene Therapy年度引用

書目名稱Cancer Gene Therapy年度引用學(xué)科排名

書目名稱Cancer Gene Therapy讀者反饋

書目名稱Cancer Gene Therapy讀者反饋學(xué)科排名

作者: flammable 時(shí)間: 2025-3-21 22:06
Polyoma and Papilloma Virus Vectors For Cancer Gene Therapyattempted, or where viruses (for example, papillo-maviruses, Epstein Barr virus, or herpesvirus-8) have been implicated in tumour formation, an approach aimed at inhibiting expression of identified oncogenic functions could be explored. These methods, coupled with stimulation of T cell killing by el

作者: Oratory 時(shí)間: 2025-3-22 04:29
Killer/DR5, A Novel DNA-Damage Inducible Death Receptor Gene, Links the p53-Tumor Suppressor to Casp for cancer treatment. TRAIL appears to be a cancer-specific cytotoxic agent and thus offers promise as a novel therapy for cancer either through replacement of the cytokine or potentially via gene replacement. Preliminary studies suggest the potential to combine TRAIL with classical cytotoxic chemo

作者: 清澈 時(shí)間: 2025-3-22 05:29

作者: 明確 時(shí)間: 2025-3-22 09:25
Book 2002em of transferring the therapeutic gene into the cancer cell has been partly addressed with major developments in the field of naked plasmid DNA, adenovirus, retrovirus and adeno-associated viruses. However, further improvements are yet to be made to achieve significant gene transfer. Gene expressio

作者: FUSC 時(shí)間: 2025-3-22 16:14
Erik Cuevas,Fernando Fausto,Adrián Gonzálezare rapidly growing with new journals and meetings solely devoted to this subject increasing annually. Within the next 5 years, we should have mean-ingful clinical data on targetable vectors to reassess our progress.

作者: FUSC 時(shí)間: 2025-3-22 18:33
J. Delgado,E. A. Lacomba,E. Pérez-Chavelaattempted, or where viruses (for example, papillo-maviruses, Epstein Barr virus, or herpesvirus-8) have been implicated in tumour formation, an approach aimed at inhibiting expression of identified oncogenic functions could be explored. These methods, coupled with stimulation of T cell killing by el

作者: Flagging 時(shí)間: 2025-3-22 22:14
https://doi.org/10.1007/978-4-431-68093-2 for cancer treatment. TRAIL appears to be a cancer-specific cytotoxic agent and thus offers promise as a novel therapy for cancer either through replacement of the cytokine or potentially via gene replacement. Preliminary studies suggest the potential to combine TRAIL with classical cytotoxic chemo

作者: CANT 時(shí)間: 2025-3-23 03:45

作者: Myofibrils 時(shí)間: 2025-3-23 07:55
The Use Of Skeletal Muscle To Express Genes For The Treatment Of Cancer

作者: Gastric 時(shí)間: 2025-3-23 11:50

作者: 粗魯性質(zhì) 時(shí)間: 2025-3-23 17:55

作者: Enliven 時(shí)間: 2025-3-23 21:30

作者: 真繁榮 時(shí)間: 2025-3-24 00:20

作者: Introvert 時(shí)間: 2025-3-24 06:22

作者: Minikin 時(shí)間: 2025-3-24 10:28

作者: 失誤 時(shí)間: 2025-3-24 11:40

作者: exophthalmos 時(shí)間: 2025-3-24 18:34
J. Delgado,E. A. Lacomba,E. Pérez-Chavelahe systems require further attention. Present vectors vary widely in efficacy of DNA transfer, and parameters important in regulating this process need to be more clearly defined. Following establishment of a generalised prototype, modifications could then be made to target specifically to tumours,

作者: 細(xì)絲 時(shí)間: 2025-3-24 21:42
https://doi.org/10.1007/978-4-431-68093-2 apoptosis through caspase activation through an as yet unclear signaling pathway that does not require the FADD adaptor. The TRAIL receptor KILLER/DR5, is induced by DNA damage and appears to be regulated by the tumor suppressor gene p53. Both the Fas receptor and KILLER/DR5 provide potential links

作者: 反感 時(shí)間: 2025-3-25 00:49

作者: Gum-Disease 時(shí)間: 2025-3-25 07:05
https://doi.org/10.1007/978-4-431-68093-2 Adenoviruses are currently the most promising vectors for gene therapy of malignant glioma especially because of their high efficiency of gene transfer. Experiences from preclinical in vitro and in vivo studies are promising and in the near future the first reports of clinical phase I and II studie

作者: 發(fā)展 時(shí)間: 2025-3-25 08:21
New Advances in Distributed Computer Systemsed investigational gene therapy protocols. Several studies have shown a potential modality of p53 gene transfer in cancer gene therapy. We also developed a new recombinant adenovirus carrying a wild-type p53 gene (AxCAp53). Although the efficacy of AxCAp53 to suppression of cell growth was not suffi

作者: 松軟 時(shí)間: 2025-3-25 11:59

作者: ANN 時(shí)間: 2025-3-25 18:30

作者: Incompetent 時(shí)間: 2025-3-25 23:00
https://doi.org/10.1007/978-3-031-30247-3f genes can be expressed in an HCC-specific manner under the control of the AFP regulatory sequences . and .. It would appear that, with the development of a suitable delivery system, HCC-directed gene therapy using the AFP regulatory sequences holds a promising future.

作者: cortex 時(shí)間: 2025-3-26 03:53
Human , Transcriptional Regulatory Sequencesf genes can be expressed in an HCC-specific manner under the control of the AFP regulatory sequences . and .. It would appear that, with the development of a suitable delivery system, HCC-directed gene therapy using the AFP regulatory sequences holds a promising future.

作者: Expiration 時(shí)間: 2025-3-26 05:02
Souvik Sarker,Md. Mujibor RahmanMan has evolved sophisticated defence mechanisms over millions of years to combat insertion of foreign DNA into his cells. However, gene therapy carries huge potential for the treatment of cancer. The challenge is therefore to translate our scien-tific knowledge into a clinical reality.

作者: 雄偉 時(shí)間: 2025-3-26 10:54
Management Problems in OncologyMan has evolved sophisticated defence mechanisms over millions of years to combat insertion of foreign DNA into his cells. However, gene therapy carries huge potential for the treatment of cancer. The challenge is therefore to translate our scien-tific knowledge into a clinical reality.

作者: 使聲音降低 時(shí)間: 2025-3-26 16:37

作者: 遣返回國 時(shí)間: 2025-3-26 20:38
Vikas Rawat,Shekhar Singh,Mahabir Singh Negigh titers and have level transgene expression are likely to have minimum immunological responses the most common problem associated with adenoviruses. It is encouraging to note that in Phase I clinical trials, first generation adenoviral vectors have been found to be fairly safe.

作者: Seminar 時(shí)間: 2025-3-26 21:42

作者: 官僚統(tǒng)治 時(shí)間: 2025-3-27 01:29
T. W. Calvert,C. Welman,S. Gaudet,C. Leepoptin treatment are expected to be minor. . results with a first prototype of anti-tumor therapy based on expression of Apoptin indicate that Apoptin has low acute toxicity and is effective as an anti-tumor agent.

作者: 壯觀的游行 時(shí)間: 2025-3-27 07:40

作者: 地名詞典 時(shí)間: 2025-3-27 11:12
Tumor-Targeted ,ly within tumors. The delay in tumor growth results in mice that survive up to twice as long. These bacteria are susceptible to a wide range of antibiotics, allowing external control of the vector after administration. The combination of these features within a single vector seems especially surprising considering their unlikely source.

作者: NOT 時(shí)間: 2025-3-27 16:25

作者: 斷斷續(xù)續(xù) 時(shí)間: 2025-3-27 18:58
0065-2598 Today we have at our disposal the technology to diagnose abnormalities in our cancer genes and the means to correct the deficit and very soon we will have the complete sequence of the human genome. With the use of gene chip technology the way doctors will be able to assess patients will change comp

作者: 非實(shí)體 時(shí)間: 2025-3-28 01:49

作者: Pantry 時(shí)間: 2025-3-28 04:02

作者: ANTE 時(shí)間: 2025-3-28 07:55

作者: 馬賽克 時(shí)間: 2025-3-28 11:57

作者: fiction 時(shí)間: 2025-3-28 15:59

作者: parallelism 時(shí)間: 2025-3-28 21:40

作者: DECRY 時(shí)間: 2025-3-29 01:37
Human , Transcriptional Regulatory Sequencesf genes can be expressed in an HCC-specific manner under the control of the AFP regulatory sequences . and .. It would appear that, with the development of a suitable delivery system, HCC-directed gene therapy using the AFP regulatory sequences holds a promising future.

作者: 高興去去 時(shí)間: 2025-3-29 07:09

作者: 不可磨滅 時(shí)間: 2025-3-29 09:37
Polyoma and Papilloma Virus Vectors For Cancer Gene Therapyhe systems require further attention. Present vectors vary widely in efficacy of DNA transfer, and parameters important in regulating this process need to be more clearly defined. Following establishment of a generalised prototype, modifications could then be made to target specifically to tumours,

作者: mechanism 時(shí)間: 2025-3-29 14:00
Killer/DR5, A Novel DNA-Damage Inducible Death Receptor Gene, Links the p53-Tumor Suppressor to Casp apoptosis through caspase activation through an as yet unclear signaling pathway that does not require the FADD adaptor. The TRAIL receptor KILLER/DR5, is induced by DNA damage and appears to be regulated by the tumor suppressor gene p53. Both the Fas receptor and KILLER/DR5 provide potential links

作者: Measured 時(shí)間: 2025-3-29 16:45